Last reviewed · How we verify
Travacom
Travacom, marketed by Alcon Research, is an established product in its therapeutic class. The key composition patent for Travacom is set to expire in 2028, providing a significant period of market exclusivity. The primary risk to Travacom's market position is the potential for generic competition following the 2028 patent expiry.
At a glance
| Generic name | Travacom |
|---|---|
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Travacom Post Marketing Surveillance Study (PHASE4)
- To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travacom CI brief — competitive landscape report
- Travacom updates RSS · CI watch RSS
- Alcon Research portfolio CI